| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Marijuana Abuse | 23 | 2021 | 251 | 2.880 |
Why?
|
| Diabetes Mellitus, Type 1 | 16 | 2022 | 529 | 2.220 |
Why?
|
| Progesterone | 5 | 2022 | 115 | 1.760 |
Why?
|
| Smoking Cessation | 19 | 2023 | 1034 | 1.570 |
Why?
|
| Mindfulness | 2 | 2021 | 41 | 1.300 |
Why?
|
| Stress, Psychological | 15 | 2022 | 824 | 1.200 |
Why?
|
| Acetylcysteine | 12 | 2021 | 296 | 1.120 |
Why?
|
| Diabetic Nephropathies | 4 | 2022 | 161 | 1.060 |
Why?
|
| Saliva | 6 | 2022 | 142 | 1.000 |
Why?
|
| Young Adult | 48 | 2023 | 5717 | 1.000 |
Why?
|
| Smokers | 5 | 2022 | 200 | 0.990 |
Why?
|
| Tobacco Use Disorder | 9 | 2023 | 432 | 0.980 |
Why?
|
| Cannabinoids | 6 | 2018 | 90 | 0.940 |
Why?
|
| Biomarkers | 13 | 2019 | 1593 | 0.910 |
Why?
|
| Lipoproteins, LDL | 11 | 2022 | 343 | 0.880 |
Why?
|
| Adult | 70 | 2023 | 21403 | 0.860 |
Why?
|
| Craving | 10 | 2022 | 200 | 0.820 |
Why?
|
| Antigen-Antibody Complex | 8 | 2019 | 175 | 0.820 |
Why?
|
| Estradiol | 3 | 2020 | 176 | 0.820 |
Why?
|
| Substance-Related Disorders | 4 | 2021 | 1242 | 0.810 |
Why?
|
| Disease Progression | 11 | 2019 | 1038 | 0.790 |
Why?
|
| Cues | 16 | 2020 | 654 | 0.780 |
Why?
|
| Double-Blind Method | 26 | 2023 | 1738 | 0.770 |
Why?
|
| Cocaine-Related Disorders | 9 | 2020 | 504 | 0.750 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2022 | 161 | 0.750 |
Why?
|
| Tobacco Smoking | 2 | 2020 | 41 | 0.740 |
Why?
|
| Female | 82 | 2022 | 38074 | 0.730 |
Why?
|
| Oxytocin | 7 | 2020 | 124 | 0.720 |
Why?
|
| Hydrocortisone | 11 | 2022 | 291 | 0.720 |
Why?
|
| Adolescent | 39 | 2023 | 8912 | 0.710 |
Why?
|
| Humans | 97 | 2023 | 68618 | 0.670 |
Why?
|
| Diabetes Complications | 4 | 2017 | 249 | 0.660 |
Why?
|
| Albuminuria | 7 | 2016 | 171 | 0.660 |
Why?
|
| Varenicline | 8 | 2023 | 98 | 0.640 |
Why?
|
| Cigarette Smoking | 4 | 2023 | 104 | 0.640 |
Why?
|
| Self Report | 4 | 2018 | 371 | 0.620 |
Why?
|
| Cannabis | 7 | 2023 | 115 | 0.600 |
Why?
|
| Glycation End Products, Advanced | 8 | 2019 | 125 | 0.590 |
Why?
|
| Male | 76 | 2022 | 37321 | 0.580 |
Why?
|
| Sex Characteristics | 9 | 2020 | 295 | 0.550 |
Why?
|
| Veterans | 2 | 2021 | 904 | 0.550 |
Why?
|
| Middle Aged | 39 | 2022 | 21147 | 0.540 |
Why?
|
| E-Selectin | 5 | 2017 | 44 | 0.530 |
Why?
|
| Marijuana Smoking | 6 | 2020 | 108 | 0.510 |
Why?
|
| Smoking | 8 | 2021 | 1452 | 0.510 |
Why?
|
| Treatment Outcome | 31 | 2023 | 7029 | 0.500 |
Why?
|
| Kidney Diseases | 1 | 2017 | 307 | 0.490 |
Why?
|
| Tobacco Products | 4 | 2021 | 234 | 0.460 |
Why?
|
| Pituitary-Adrenal System | 8 | 2022 | 138 | 0.430 |
Why?
|
| Tobacco Use Cessation | 2 | 2023 | 44 | 0.420 |
Why?
|
| Nicotinic Agonists | 5 | 2018 | 111 | 0.410 |
Why?
|
| Buspirone | 3 | 2016 | 36 | 0.390 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 3 | 2017 | 27 | 0.380 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 3 | 2017 | 27 | 0.380 |
Why?
|
| Alcohol Drinking | 4 | 2020 | 805 | 0.370 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2020 | 1506 | 0.370 |
Why?
|
| Social Environment | 3 | 2020 | 182 | 0.360 |
Why?
|
| Free Radical Scavengers | 5 | 2019 | 112 | 0.360 |
Why?
|
| Amphetamine-Related Disorders | 4 | 2012 | 92 | 0.350 |
Why?
|
| Extinction, Psychological | 4 | 2020 | 240 | 0.350 |
Why?
|
| Ascitic Fluid | 1 | 2009 | 22 | 0.350 |
Why?
|
| Hypothalamo-Hypophyseal System | 7 | 2022 | 150 | 0.340 |
Why?
|
| Sphingolipids | 4 | 2022 | 337 | 0.340 |
Why?
|
| Paracentesis | 1 | 2009 | 25 | 0.340 |
Why?
|
| Ascites | 1 | 2009 | 38 | 0.340 |
Why?
|
| Menstrual Cycle | 2 | 2022 | 64 | 0.330 |
Why?
|
| Inflammation | 5 | 2017 | 1030 | 0.330 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 4 | 2017 | 58 | 0.330 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2022 | 1085 | 0.310 |
Why?
|
| Kidney | 3 | 2022 | 945 | 0.300 |
Why?
|
| Counseling | 4 | 2019 | 280 | 0.300 |
Why?
|
| Serotonin Receptor Agonists | 3 | 2016 | 34 | 0.290 |
Why?
|
| Behavior, Addictive | 3 | 2020 | 317 | 0.280 |
Why?
|
| Recurrence | 6 | 2021 | 948 | 0.270 |
Why?
|
| Follow-Up Studies | 10 | 2019 | 3259 | 0.270 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 2 | 2017 | 15 | 0.270 |
Why?
|
| Quinoxalines | 3 | 2015 | 78 | 0.260 |
Why?
|
| Yohimbine | 2 | 2017 | 41 | 0.260 |
Why?
|
| Benzazepines | 3 | 2015 | 104 | 0.260 |
Why?
|
| Behavior Therapy | 4 | 2021 | 297 | 0.260 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2023 | 189 | 0.260 |
Why?
|
| Cognition Disorders | 3 | 2015 | 342 | 0.260 |
Why?
|
| Prospective Studies | 6 | 2020 | 3705 | 0.260 |
Why?
|
| Cocaine | 2 | 2022 | 555 | 0.250 |
Why?
|
| Substance Withdrawal Syndrome | 4 | 2018 | 435 | 0.240 |
Why?
|
| Adaptation, Psychological | 2 | 2018 | 447 | 0.240 |
Why?
|
| Research Design | 2 | 2019 | 729 | 0.230 |
Why?
|
| Dronabinol | 3 | 2019 | 84 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2022 | 931 | 0.220 |
Why?
|
| Alcoholism | 3 | 2022 | 1109 | 0.220 |
Why?
|
| Luteal Phase | 1 | 2022 | 25 | 0.210 |
Why?
|
| Malondialdehyde | 5 | 2016 | 43 | 0.210 |
Why?
|
| Apolipoproteins M | 1 | 2022 | 5 | 0.210 |
Why?
|
| Diabetic Retinopathy | 2 | 2014 | 110 | 0.210 |
Why?
|
| Anxiety | 3 | 2017 | 422 | 0.210 |
Why?
|
| Interleukin-6 | 4 | 2017 | 330 | 0.210 |
Why?
|
| Inflammation Mediators | 2 | 2014 | 244 | 0.210 |
Why?
|
| Sex Factors | 7 | 2020 | 1266 | 0.200 |
Why?
|
| Atherosclerosis | 2 | 2015 | 204 | 0.200 |
Why?
|
| Methylprednisolone | 2 | 2013 | 99 | 0.200 |
Why?
|
| C-Reactive Protein | 3 | 2017 | 180 | 0.200 |
Why?
|
| Autoantibodies | 2 | 2016 | 434 | 0.200 |
Why?
|
| Diabetic Angiopathies | 2 | 2015 | 203 | 0.200 |
Why?
|
| Drug-Seeking Behavior | 2 | 2017 | 213 | 0.190 |
Why?
|
| Ceramides | 2 | 2016 | 578 | 0.190 |
Why?
|
| Heart Rate | 4 | 2019 | 568 | 0.190 |
Why?
|
| Medical Marijuana | 2 | 2018 | 21 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 148 | 0.190 |
Why?
|
| Pilot Projects | 7 | 2021 | 1342 | 0.190 |
Why?
|
| Vaping | 1 | 2022 | 124 | 0.180 |
Why?
|
| Glucocorticoids | 2 | 2013 | 222 | 0.180 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2017 | 45 | 0.180 |
Why?
|
| Smoking Prevention | 3 | 2017 | 259 | 0.180 |
Why?
|
| Medication Adherence | 4 | 2019 | 335 | 0.180 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2022 | 180 | 0.180 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2020 | 52 | 0.180 |
Why?
|
| Heroin Dependence | 1 | 2020 | 23 | 0.170 |
Why?
|
| Neoplasms | 2 | 2021 | 1667 | 0.170 |
Why?
|
| Blood Coagulation | 2 | 2017 | 123 | 0.170 |
Why?
|
| Restraint, Physical | 1 | 2020 | 59 | 0.170 |
Why?
|
| Ovary | 1 | 2020 | 99 | 0.170 |
Why?
|
| Secondary Prevention | 1 | 2021 | 291 | 0.170 |
Why?
|
| Motivational Interviewing | 2 | 2017 | 40 | 0.170 |
Why?
|
| Heroin | 1 | 2020 | 49 | 0.170 |
Why?
|
| False Negative Reactions | 1 | 2019 | 63 | 0.160 |
Why?
|
| Administration, Intranasal | 4 | 2020 | 88 | 0.160 |
Why?
|
| Stress, Physiological | 1 | 2020 | 215 | 0.160 |
Why?
|
| Adrenocorticotropic Hormone | 4 | 2011 | 106 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 446 | 0.160 |
Why?
|
| Methamphetamine | 2 | 2010 | 132 | 0.160 |
Why?
|
| Combined Modality Therapy | 6 | 2017 | 951 | 0.150 |
Why?
|
| Motivation | 5 | 2021 | 561 | 0.150 |
Why?
|
| Implosive Therapy | 1 | 2020 | 171 | 0.150 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2013 | 450 | 0.150 |
Why?
|
| Substance Abuse Detection | 1 | 2018 | 66 | 0.150 |
Why?
|
| Fibrinolysis | 1 | 2017 | 55 | 0.150 |
Why?
|
| Lipoproteins | 2 | 2022 | 161 | 0.150 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2017 | 52 | 0.150 |
Why?
|
| Fibrinogen | 1 | 2017 | 87 | 0.150 |
Why?
|
| Health Services Research | 1 | 2019 | 209 | 0.150 |
Why?
|
| Triglycerides | 1 | 2017 | 184 | 0.140 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2015 | 54 | 0.140 |
Why?
|
| Myocardial Infarction | 2 | 2012 | 807 | 0.140 |
Why?
|
| Diabetic Neuropathies | 1 | 2016 | 33 | 0.140 |
Why?
|
| Underage Drinking | 1 | 2016 | 25 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 498 | 0.140 |
Why?
|
| Cholesterol | 1 | 2017 | 331 | 0.130 |
Why?
|
| Ultrasonography | 4 | 2011 | 453 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 2279 | 0.130 |
Why?
|
| Vilazodone Hydrochloride | 1 | 2015 | 6 | 0.130 |
Why?
|
| Psychomotor Performance | 2 | 2015 | 213 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2018 | 468 | 0.130 |
Why?
|
| Predictive Value of Tests | 6 | 2017 | 1465 | 0.130 |
Why?
|
| Corticotropin-Releasing Hormone | 3 | 2011 | 79 | 0.130 |
Why?
|
| Cognition | 3 | 2020 | 513 | 0.130 |
Why?
|
| Endothelium, Vascular | 2 | 2015 | 371 | 0.130 |
Why?
|
| Nicotine | 2 | 2018 | 350 | 0.130 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2015 | 20 | 0.130 |
Why?
|
| Riboflavin | 1 | 2015 | 15 | 0.130 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 2077 | 0.130 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2015 | 12 | 0.130 |
Why?
|
| Learning | 1 | 2017 | 186 | 0.120 |
Why?
|
| Memory | 2 | 2015 | 214 | 0.120 |
Why?
|
| Guanfacine | 1 | 2014 | 6 | 0.120 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2014 | 11 | 0.120 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 121 | 0.120 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 298 | 0.120 |
Why?
|
| Pregnancy in Diabetics | 1 | 2015 | 70 | 0.120 |
Why?
|
| Aged | 6 | 2018 | 14862 | 0.120 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2013 | 250 | 0.120 |
Why?
|
| Social Behavior | 1 | 2015 | 164 | 0.120 |
Why?
|
| Diabetes, Gestational | 1 | 2015 | 81 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2015 | 111 | 0.110 |
Why?
|
| Connectome | 1 | 2015 | 92 | 0.110 |
Why?
|
| Cohort Studies | 6 | 2016 | 2358 | 0.110 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2015 | 138 | 0.110 |
Why?
|
| Apolipoproteins | 1 | 2013 | 51 | 0.110 |
Why?
|
| Attitude to Health | 1 | 2016 | 403 | 0.110 |
Why?
|
| Neural Pathways | 1 | 2015 | 324 | 0.110 |
Why?
|
| Preoperative Care | 2 | 2013 | 275 | 0.110 |
Why?
|
| Ultrasonography, Mammary | 1 | 2013 | 39 | 0.110 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2017 | 413 | 0.110 |
Why?
|
| Propranolol | 1 | 2013 | 103 | 0.110 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2012 | 59 | 0.110 |
Why?
|
| Quality of Life | 1 | 2021 | 1515 | 0.110 |
Why?
|
| Time Factors | 7 | 2015 | 4655 | 0.110 |
Why?
|
| Depression | 1 | 2019 | 943 | 0.100 |
Why?
|
| Cytokines | 2 | 2014 | 866 | 0.100 |
Why?
|
| South Carolina | 5 | 2020 | 2752 | 0.100 |
Why?
|
| Biliary Dyskinesia | 1 | 2011 | 7 | 0.100 |
Why?
|
| Cycloserine | 1 | 2012 | 30 | 0.100 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2012 | 128 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 940 | 0.100 |
Why?
|
| Tobacco | 2 | 2023 | 161 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2020 | 7277 | 0.100 |
Why?
|
| Durapatite | 1 | 2011 | 33 | 0.100 |
Why?
|
| Microspheres | 1 | 2011 | 59 | 0.100 |
Why?
|
| Cholesterol, LDL | 1 | 2012 | 161 | 0.100 |
Why?
|
| Prevalence | 4 | 2020 | 1619 | 0.100 |
Why?
|
| United States | 3 | 2020 | 7367 | 0.100 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2011 | 85 | 0.090 |
Why?
|
| Tunica Media | 1 | 2010 | 33 | 0.090 |
Why?
|
| Tunica Intima | 1 | 2010 | 59 | 0.090 |
Why?
|
| Fear | 1 | 2012 | 239 | 0.090 |
Why?
|
| Immunity, Humoral | 1 | 2010 | 42 | 0.090 |
Why?
|
| Arousal | 1 | 2011 | 168 | 0.090 |
Why?
|
| Carotid Arteries | 1 | 2010 | 110 | 0.090 |
Why?
|
| Coronary Circulation | 1 | 2011 | 136 | 0.090 |
Why?
|
| Bupropion | 1 | 2010 | 63 | 0.090 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2011 | 106 | 0.090 |
Why?
|
| Association Learning | 1 | 2010 | 36 | 0.090 |
Why?
|
| Prosthesis Implantation | 1 | 2011 | 83 | 0.090 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2010 | 151 | 0.090 |
Why?
|
| Comorbidity | 3 | 2019 | 1426 | 0.090 |
Why?
|
| Matrix Metalloproteinases | 1 | 2011 | 223 | 0.090 |
Why?
|
| Life Change Events | 1 | 2011 | 223 | 0.090 |
Why?
|
| Tobacco Use | 2 | 2022 | 98 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 234 | 0.080 |
Why?
|
| Calcinosis | 1 | 2010 | 241 | 0.080 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2010 | 152 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2022 | 139 | 0.080 |
Why?
|
| Risk Factors | 6 | 2019 | 5731 | 0.080 |
Why?
|
| Conditioning, Operant | 1 | 2010 | 241 | 0.080 |
Why?
|
| Ventricular Remodeling | 1 | 2011 | 318 | 0.080 |
Why?
|
| Extracellular Matrix | 1 | 2011 | 493 | 0.080 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 567 | 0.080 |
Why?
|
| Hemodynamics | 1 | 2011 | 705 | 0.080 |
Why?
|
| Rural Population | 1 | 2011 | 398 | 0.080 |
Why?
|
| Adolescent Behavior | 1 | 2010 | 264 | 0.080 |
Why?
|
| Incidence | 3 | 2019 | 1603 | 0.070 |
Why?
|
| Psychological Tests | 3 | 2013 | 96 | 0.070 |
Why?
|
| Neuropsychological Tests | 3 | 2015 | 517 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1140 | 0.070 |
Why?
|
| Neurosecretory Systems | 2 | 2020 | 21 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2014 | 2800 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2017 | 260 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2010 | 696 | 0.060 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 848 | 0.060 |
Why?
|
| Brain | 1 | 2015 | 2176 | 0.060 |
Why?
|
| Dehydroepiandrosterone | 2 | 2014 | 29 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 1536 | 0.050 |
Why?
|
| Tablets | 1 | 2022 | 19 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2016 | 880 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2014 | 2007 | 0.050 |
Why?
|
| Lactosylceramides | 1 | 2022 | 27 | 0.050 |
Why?
|
| Immunoglobulin G | 2 | 2016 | 481 | 0.050 |
Why?
|
| Clonidine | 1 | 2021 | 66 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2021 | 50 | 0.050 |
Why?
|
| Patient Selection | 2 | 2019 | 592 | 0.050 |
Why?
|
| Neuroendocrine Cells | 1 | 2020 | 8 | 0.050 |
Why?
|
| Photic Stimulation | 2 | 2012 | 229 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2013 | 737 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 792 | 0.040 |
Why?
|
| Odorants | 1 | 2020 | 52 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 955 | 0.040 |
Why?
|
| Child | 4 | 2010 | 6405 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 442 | 0.040 |
Why?
|
| Glycosylation | 1 | 2019 | 185 | 0.040 |
Why?
|
| Research | 1 | 2019 | 214 | 0.040 |
Why?
|
| Self Administration | 1 | 2020 | 419 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 38 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 352 | 0.040 |
Why?
|
| Sulpiride | 1 | 2017 | 20 | 0.040 |
Why?
|
| Placebos | 1 | 2017 | 195 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2010 | 782 | 0.040 |
Why?
|
| Help-Seeking Behavior | 1 | 2017 | 13 | 0.040 |
Why?
|
| Oxytocics | 1 | 2017 | 14 | 0.040 |
Why?
|
| Ecological Momentary Assessment | 1 | 2016 | 16 | 0.040 |
Why?
|
| Prognosis | 2 | 2012 | 2093 | 0.040 |
Why?
|
| Patient Care Management | 1 | 2017 | 40 | 0.030 |
Why?
|
| Mental Recall | 1 | 2017 | 72 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 2016 | 14 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2016 | 39 | 0.030 |
Why?
|
| Logistic Models | 2 | 2010 | 1420 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2013 | 2455 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2013 | 1451 | 0.030 |
Why?
|
| Glycosphingolipids | 1 | 2016 | 51 | 0.030 |
Why?
|
| Sphingomyelins | 1 | 2016 | 106 | 0.030 |
Why?
|
| Cysteine | 1 | 2016 | 112 | 0.030 |
Why?
|
| Amino Acids | 1 | 2016 | 131 | 0.030 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2015 | 11 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1864 | 0.030 |
Why?
|
| Epitopes | 1 | 2016 | 146 | 0.030 |
Why?
|
| Birth Certificates | 1 | 2015 | 16 | 0.030 |
Why?
|
| Transdermal Patch | 1 | 2015 | 21 | 0.030 |
Why?
|
| Maternal Age | 1 | 2015 | 70 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 2083 | 0.030 |
Why?
|
| Retinal Vasculitis | 1 | 2014 | 8 | 0.030 |
Why?
|
| Role | 1 | 2014 | 25 | 0.030 |
Why?
|
| Alleles | 1 | 2015 | 386 | 0.030 |
Why?
|
| Women's Health | 1 | 2015 | 148 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2013 | 56 | 0.030 |
Why?
|
| Nasal Sprays | 1 | 2013 | 11 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 411 | 0.030 |
Why?
|
| Animals | 3 | 2020 | 20881 | 0.030 |
Why?
|
| Temperance | 1 | 2013 | 41 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2013 | 85 | 0.030 |
Why?
|
| Health Surveys | 1 | 2015 | 489 | 0.030 |
Why?
|
| Taurine | 1 | 2013 | 51 | 0.030 |
Why?
|
| Psychotherapy | 1 | 2015 | 253 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2013 | 57 | 0.030 |
Why?
|
| Immunoassay | 1 | 2013 | 64 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 111 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2015 | 239 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2015 | 402 | 0.030 |
Why?
|
| Alcohol Deterrents | 1 | 2013 | 86 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2013 | 113 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 142 | 0.030 |
Why?
|
| Health Behavior | 1 | 2016 | 458 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2013 | 129 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2013 | 172 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 189 | 0.030 |
Why?
|
| Gallbladder Emptying | 1 | 2011 | 4 | 0.030 |
Why?
|
| Imino Acids | 1 | 2011 | 7 | 0.030 |
Why?
|
| ROC Curve | 1 | 2013 | 392 | 0.020 |
Why?
|
| Cholecystokinin | 1 | 2011 | 29 | 0.020 |
Why?
|
| Prefrontal Cortex | 1 | 2017 | 640 | 0.020 |
Why?
|
| Technetium | 1 | 2011 | 38 | 0.020 |
Why?
|
| Rats | 1 | 2020 | 5300 | 0.020 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2011 | 24 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2013 | 184 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2013 | 210 | 0.020 |
Why?
|
| Naltrexone | 1 | 2013 | 195 | 0.020 |
Why?
|
| Injections | 1 | 2011 | 119 | 0.020 |
Why?
|
| Reaction Time | 1 | 2012 | 170 | 0.020 |
Why?
|
| Sheep | 1 | 2011 | 128 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2017 | 659 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 329 | 0.020 |
Why?
|
| Cardiac Output, Low | 1 | 2011 | 52 | 0.020 |
Why?
|
| Motor Skills | 1 | 2011 | 88 | 0.020 |
Why?
|
| Vasodilation | 1 | 2011 | 85 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2011 | 168 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2011 | 91 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 160 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2011 | 172 | 0.020 |
Why?
|
| Ventricular Pressure | 1 | 2011 | 82 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 279 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 252 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2011 | 163 | 0.020 |
Why?
|
| Cotinine | 1 | 2010 | 40 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2010 | 120 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2010 | 134 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 43 | 0.020 |
Why?
|
| Self Disclosure | 1 | 2010 | 55 | 0.020 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2011 | 174 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 85 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 682 | 0.020 |
Why?
|
| Galvanic Skin Response | 1 | 2010 | 67 | 0.020 |
Why?
|
| Length of Stay | 1 | 2013 | 780 | 0.020 |
Why?
|
| Particle Size | 1 | 2010 | 201 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2011 | 333 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2011 | 301 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1054 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2013 | 448 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 546 | 0.020 |
Why?
|
| Swine | 1 | 2011 | 672 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 2334 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 1040 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 508 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1851 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2011 | 323 | 0.020 |
Why?
|
| Collagen | 1 | 2011 | 636 | 0.020 |
Why?
|
| Child Abuse | 1 | 2010 | 186 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 595 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 536 | 0.020 |
Why?
|
| Central Nervous System Stimulants | 1 | 2010 | 221 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 714 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 362 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2011 | 481 | 0.020 |
Why?
|
| Insulin | 1 | 2010 | 619 | 0.020 |
Why?
|
| Heart Defects, Congenital | 1 | 2011 | 596 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2010 | 866 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 2550 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2011 | 1615 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2011 | 2689 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 2324 | 0.010 |
Why?
|